{
    "clinical_study": {
        "@rank": "88933", 
        "arm_group": [
            {
                "arm_group_label": "GlucoTab System", 
                "arm_group_type": "Experimental", 
                "description": "Investigational system: GlucoTab system supports the glycaemic management of non-critically ill patients with type two diabetes at the general ward."
            }, 
            {
                "arm_group_label": "no intervention", 
                "arm_group_type": "No Intervention", 
                "description": "standard care"
            }
        ], 
        "brief_summary": {
            "textblock": "Objective: To investigate the performance (safety) of the GlucoTab system for glycaemic\n      management in non-critically ill patients with type 2 diabetes at the general ward"
        }, 
        "brief_title": "Performance of a Tablet Based Workflow and Decision Support System With Incorporated Software Algorithm Used for Glycaemic Management", 
        "completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "condition": "Type 2 Diabetes", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Informed consent obtained after being advised of the nature of the study\n\n          -  Male or female aged 18 - 90 years (both inclusive)\n\n          -  Type 2 diabetes treated with diet, oral agents, non-insulin injected anti-diabetic\n             medicine, insulin therapy or any combination of the four\n\n        Exclusion Criteria:\n\n          -  Impaired renal function (serum creatinine \u22653.0mg/dL)\n\n          -  Any disease or condition which the investigator or treating physician feels would\n             interfere with the trial or the safety of the patient\n\n          -  Pregnancy\n\n          -  Any mental condition rendering the patient incapable of giving his consent\n\n          -  Terminally ill patients\n\n          -  Participation in a trial within 3 months prior to this trial\n\n          -  Known or suspected allergy to insulin"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01766752", 
            "org_study_id": "ClinDiab-03"
        }, 
        "intervention": {
            "arm_group_label": "GlucoTab System", 
            "description": "Tablet based workflow and decision support system with incorporated software algorithm (GlucoTab) used for glycaemic management in non-critically ill patients with type 2 diabetes at the general ward", 
            "intervention_name": "GlucoTab System", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 9, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Graz", 
                    "country": "Austria", 
                    "zip": "8036"
                }, 
                "name": "Medical University of Graz"
            }
        }, 
        "location_countries": {
            "country": "Austria"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open, Single-centre, Non-controlled Feasibility Study of the Performance of a Tablet Based Workflow and Decision Support System With Incorporated Software Algorithm Used for Glycaemic Management in Non-critically Ill Patients With Type 2 Diabetes at the General Ward", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Austria: The Austrian Agency for Health and Food Safety"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "The primary endpoint is the percentage of actions the system supports either to capture BG values or provide insulin dose suggestions according to the REACTION algorithm.", 
            "safety_issue": "Yes", 
            "time_frame": "duration of hospital stay (maximum three weeks)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01766752"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Medical University of Graz", 
            "investigator_full_name": "Pieber Thomas, MD", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Medical University of Graz", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Medical University of Graz", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}